Baraclude Bristol-Myers Squibb Company - Treatment for Chronic Hepatitis BBaraclude is a nucleoside analogue oral antiviral therapy that works by interfering with viral reproduction. Baraclude is indicated for the treatment of chronic hepatitis B in adults.
Posted: March 2005
- U.S. Food and Drug Administration Approves Baraclude (entecavir) as a Treatment for Chronic Hepatitis B Patients with Evidence of Decompensated Liver Disease - October 18, 2010
- Bristol-Myers Squibb Statement on FDA Advisory Committee Vote on Baraclude (entecavir), an Investigational Oral Antiviral Agent for Chronic Hepatitis B - March 11, 2005
- Bristol-Myers Squibb Submits Applications in U.S. and Europe to Market Entecavir, an Investigational Antiviral Treatment For Chronic Hepatitis B Infection - October 4, 2004
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.